---
title: "Lofexidine and Opioid Withdrawal: Beyond the Impact of Blood Pressure"
author: "Zakk Heile, Kanthi Makineedi, Matthew O'Donnell, Yash Singam, Lisa Zhang and Raphael Morsomme"
footer: "Introduction to Undergraduate Research in Statistics Workshop (2024)"
logo: "figures/duke.svg"
format:
  revealjs: 
    slide-number: true
    scrollable: true
    self-contained: true
    theme: default
---

## Reexamining Previous Study

-   Lofexidine: mitigates opioid withdrawal

-   Reduces withdrawal severity with fewer side effects compared to similar treatments

-   Current Knowledge: Lofexidine found to lower blood pressure

. . .

::: {.callout-note icon="false"}
## Our Study

-   Goal: Does Lofexidine impact withdrawal beyond blood pressure?
-   Impact: There may be better (cheaper or more targeted) treatments for withdrawal
:::

## Data

-   Predominantly male sample (87%)

-   Small sample size (68), limits generalizability

-   Participants have a history of opioid dependence

## Linear Regression Model

```{=tex}
\begin{equation}
\label{eq:model}
y_i = \alpha + \beta z_i + \gamma^T x_i + \epsilon_i, \qquad i=1,2,\dots,44,
\end{equation}
```
::: columns
::: {.column width="45%"}
#### Model Parameters

-   Intercept: $\alpha$
-   Treatment effect: $\beta$
-   Regression coefficients: $\gamma$
:::

::: {.column width="10%"}
<!-- empty column to create gap -->
:::

::: {.column width="45%"}
#### Variables

-   MHOWS: $y_i$
-   Treatment: $z_i\in\{0,1\}$
-   Covariates: $x_i\in R^2$
-   Error: $\epsilon_i \overset{\text{i.i.d.}}{\sim} N(0, \sigma^2)$
:::
:::

## Cohort Mean for Potential Covariates

| Covariate                        | Lofexidine | Placebo | Total |
|----------------------------------|:----------:|:-------:|:-----:|
| [**Age***]{style="color:red;"} |    42.0    |  40.5   | 41.3  |
| \% Male                          |   88.6%    |  84.8%  | 86.8% |
| Opioid Use                       |    29.4    |  29.2   | 29.3  |
| [**Tobacco Use***]{style="color:red;"}                |   19.43    |  19.48  | 19.46 |
| Baseline BP                      |   123.0    |  123.2  | 123.1 |

[***Chosen for final model**]{style="color:red;"}

## Response Variable

Composite MHOWS score excluding blood pressure

-   Day 5

-   Discrete MHOWS variables
    -   anorexia score imputation
    -   conversion to factors
    
-   Continuous MHOWS variables
    -   imputation of missing values
    -   calculate comparisons to baseline (day 1 and/or 2)
    
## Results
::: {.panel-tabset}

## Treatment Visualization

![](figures/boxplot_sbs.jpg){fig-align="center" width="60%"}


## Sensitivity Analysis

| Predictor       | M.L.E.  | p-value  |
|------------|-----------|----------|
| Intercept  | 5.505 / 5.343     | 0.829 / 0.834    |
| Age        | 0.736 / 0.740     | 0.218 / 0.215    |
| Lofexidine Treatment | -16.800 / -16.912   | [**0.072 / 0.070**]{style="color:red;"}    |
| Tobacco Use    | 0.359 / 0.358   | 0.349 / 0.350    |

:::


## Discussion

-   Does Lofexidine impact withdrawal beyond blood pressure?
    -   The effect of Lofexidine is not statistically significant
    
. . .    
    
-   Future Work: 
    -   Larger sample size
    -   Better patient retention
    -   Modelling dropout

# Thank you! Questions?
